HCPCS code J2323: Natalizumab billing guide for infusion clinics

Key takeaways

HCPCS code J2323 describes Injection, natalizumab, 1 mg and is billed per 1 mg unit, so a standard 300 mg Tysabri dose requires 300 units on the claim.

J2323 is approved for relapsing multiple sclerosis (ICD-10 G35) and moderate-to-severe Crohn’s disease (ICD-10 K50.00-K50.919); prior authorization is required by most commercial payers.

CMS mandates JW or JZ modifiers on J2323 claims to report discarded drug amounts or confirm no wastage; missing either modifier triggers automatic denial.

Practice management software like Pabau helps infusion clinics track per-unit J2323 billing, modifier requirements, and REMS documentation in one place.

HCPCS code J2323 is the billing code for natalizumab injections, billed per 1 mg unit. It covers Injection, natalizumab, 1 mg, used to report infusions administered for relapsing multiple sclerosis and moderate-to-severe Crohn’s disease. The code applies to both originator Tysabri and its FDA-approved biosimilar, Tyruko, which carries a separate code and separate REMS enrollment.

This guide covers unit calculation, the ICD-10 diagnosis codes payers accept, JW and JZ modifier requirements, Medicare and commercial payer coverage, TOUCH REMS documentation, and the most common reasons J2323 claims get denied.

HCPCS code J2323: Definition, drug details, and clinical classification

HCPCS code J2323 is the billing code maintained by CMS for natalizumab injections, billed at a rate of 1 mg per unit. The full code descriptor reads: Injection, natalizumab, 1 mg.

Natalizumab is a humanized monoclonal antibody that blocks alpha-4 integrin, preventing immune cells from crossing the blood-brain barrier and the gut lining. Under the brand name Tysabri (manufactured by Biogen), it comes as a 300 mg concentrate for IV infusion.

The code falls under HCPCS Level II J-codes, specifically the category for drugs administered other than the oral method. CMS classifies HCPCS code J2323 under the BETOS category “Other Drugs.” The code was added to the HCPCS code set on January 1, 2008 and remains active in the current code year.

Practices using infusion therapy EMR workflows should note that the 300 mg vial is the only commercially available presentation. Since the code is billed per 1 mg, every standard infusion generates a claim for exactly 300 units of J2323. Billing anything other than 300 units, barring documented dose adjustments, is a red flag for audit.

Key code properties at a glance

• Code: J2323
• Full descriptor: Injection, natalizumab, 1 mg
• Short descriptor: Natalizumab injection
• Code type: HCPCS Level II J-code
• BETOS classification: Other Drugs
• Medicare coverage status: Carrier judgment
• Brand name: Tysabri (Biogen)
• Standard dose: 300 mg IV every 4 weeks
• Units per standard dose: 300
• Code effective date: January 1, 2008

Natalizumab is one of several infused disease-modifying therapies for MS. Practices that also administer ocrelizumab (Ocrevus) should reference the separate billing guide for HCPCS code J2350, since the two drugs carry different codes, dosing, and REMS obligations.

Approved indications and ICD-10 diagnosis codes for J2323

Natalizumab carries FDA approval for two distinct conditions. Getting the diagnosis code right is the first gate any claim has to pass. Payers cross-reference the submitted ICD-10 code against their coverage criteria before processing the claim.

Multiple sclerosis (Relapsing forms)

Natalizumab is approved as a monotherapy for relapsing forms of multiple sclerosis. The single ICD-10-CM code accepted for this indication is G35 (Multiple sclerosis). Per the Medi-Cal provider manual, G35 is the required diagnosis code when billing HCPCS code J2323 for MS.

Most commercial payers align with this requirement, but some additionally require documentation of prior DMT failure or an active relapse within the past 12 months.

Crohn’s disease (Moderate to severe)

Natalizumab is also FDA-approved for inducing and maintaining clinical response in adults with moderately to severely active Crohn’s disease who have had an inadequate response to or are unable to tolerate conventional therapies. The accepted ICD-10-CM code range is K50.00 through K50.919 (Crohn’s disease of small intestine).

Coverage for Crohn’s is subject to medical necessity criteria and, at many commercial payers, requires prior authorization with documentation of conventional therapy failure. Coverage is not universal across Medicaid programs, and some payers may consider it off-label.

Other biologics used for moderate-to-severe Crohn’s disease carry separate HCPCS codes, including vedolizumab (HCPCS code J3380) and the infliximab biosimilar infliximab-axxq (HCPCS code Q5121). Confirm the specific drug administered matches the code billed — these products are not interchangeable on a claim.

Submitting J2323 with an ICD-10 code outside these ranges (for example, a secondary progressive MS code alone, or a non-specific inflammatory bowel disease code) will result in denial at most payers. Review the patient’s chart documentation against the payer’s specific coverage policy before every infusion cycle.

Dosage-to-unit conversion and HCPCS code J2323 billing math

Unit conversion is where most billing errors occur with high-cost infusion drugs. The descriptor “per 1 mg” means you multiply the administered dose by 1 to get units. For natalizumab, that arithmetic is straightforward.

• Standard dose: 300 mg IV infusion every 4 weeks
• Units billed per dose: 300 (300 mg x 1 unit/mg)
• Maximum daily dosage: 300 mg (per Medi-Cal provider manual and standard labeling)
• Vial size: 300 mg/15 mL single-dose vial (20 mg/mL concentration)
• Billing frequency: One claim per infusion, typically every 28 days

This per-unit billing pattern is standard across single-agent injectables. See the separate guides for sodium ferric gluconate (HCPCS code J2916) and digoxin injection (HCPCS code J1160) for other examples of per-mg and per-unit dosing math.

Because natalizumab comes only as a single-dose 300 mg vial and the standard dose is the full 300 mg, vial wastage is not typically a factor in straightforward billing scenarios.

If a dose is interrupted or the physician orders a non-standard dose (rare but documented in pediatric or dose-adjustment contexts), account for the administered amount and any discarded remainder using JW or JZ modifiers. For IV therapy clinic best practices, always verify the administered dose against the physician order before submitting units.

JW and JZ modifier requirements for HCPCS code J2323

CMS requires JW and JZ modifiers on claims for single-dose vial drugs, including HCPCS code J2323. The CMS JW/JZ modifier policy explicitly lists J2323 as a drug subject to this requirement.

The JW modifier, used to report discarded drug, has been required since January 1, 2017. The JZ modifier, which attests that no drug was wasted, became mandatory July 1, 2023, and CMS began editing claims and issuing denials for missing modifiers in October 2023. Medicare, most Medicaid programs, and many commercial payers now enforce this requirement.

Other single-dose vial biologics carry the same JW/JZ requirement. See the separate billing guide for denosumab (HCPCS code J0897) for another worked example of the modifier logic.

JW modifier: Reporting discarded drug

The JW modifier is appended to a separate line item reporting the amount of drug discarded from a single-dose vial. If a 300 mg vial is administered in full (300 units billed) and there is no wastage, you do not use JW.

But if only 250 mg is administered and 50 mg is discarded from the vial, you bill two line items: 250 units of J2323 (administered dose) and 50 units of J2323-JW (discarded amount).

The JW line is not a $0 throwaway entry. Medicare Part B separately pays providers for the discarded amount reported with the JW modifier, up to the labeled vial size, in addition to the administered dose.

CMS also uses aggregated JW and JZ data to calculate manufacturer refunds under Social Security Act §1847A(h) — that refund is recouped from the drug manufacturer, not deducted from provider reimbursement.

JZ modifier: Confirming no wastage

The JZ modifier is appended to the primary drug line when the full vial content is administered and there is no discarded drug. For most standard natalizumab infusions (full 300 mg dose, single vial, no waste), the correct billing is 300 units of J2323-JZ.

Omitting both JW and JZ modifiers results in automatic claim rejection under CMS policy. Compliance management software with built-in modifier prompts helps prevent this common denial.

Streamline J2323 billing from infusion to reimbursement

Pabau helps infusion clinics track administered drug units, apply JW/JZ modifiers correctly, and manage prior authorization workflows, all in one practice management platform.

Book a demo

Medicare and commercial payer coverage for J2323

Medicare coverage status for HCPCS code J2323 is classified as “Carrier judgment,” meaning coverage decisions are made at the local Medicare Administrative Contractor (MAC) level rather than through a national coverage determination. In practice, natalizumab for relapsing MS and Crohn’s disease is routinely covered under Medicare Part B when medical necessity criteria are met and documentation supports the diagnosis.

Medicare Part B covers physician-administered drugs like natalizumab when they cannot be self-administered. The drug is reimbursed at ASP (Average Sales Price) + 6% in both office-based settings and hospital outpatient departments under the OPPS — the payment formula is the same across settings.

Use the CMS Physician Fee Schedule lookup tool to check the current quarter’s ASP payment amount for J2323. ASP rates update quarterly and should be verified before each billing cycle.

For mobile IV therapy workflows, note that the infusion setting affects reimbursement. Office-based infusions, hospital outpatient departments, and home infusion each carry different payment rules and rates.

Billing J2323 in a home infusion setting typically routes through Medicare Part B with the same ASP-based payment, but requires additional documentation of medical necessity for home versus outpatient administration.

Commercial payer coverage

Most major commercial payers cover natalizumab for the FDA-approved indications, typically requiring prior authorization. Blue Shield of California’s Medi-Cal medical benefit drug policy, Anthem CarelonRx, and BCBSM all list J2323 as a covered drug under their specialty pharmacy or medical benefit drug programs.

Specific clinical criteria generally include confirmed diagnosis, REMS enrollment verification, and in some cases documentation of prior treatment failure.

Coverage policies change. Always verify the current policy for each payer before the patient’s infusion cycle and document the authorization number on the claim. Prescription management software that tracks authorization expiry dates reduces the risk of infusing without active coverage.

TOUCH REMS program: Billing and documentation prerequisites for J2323

Natalizumab cannot be legally administered, dispensed, or billed without enrollment in the TOUCH Prescribing Program, an FDA-mandated Risk Evaluation and Mitigation Strategy (REMS). TOUCH stands for Tysabri Outreach: Unified Commitment to Health. The program exists because of natalizumab’s association with progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal brain infection caused by the JC virus.

REMS enrollment is a billing prerequisite, not merely a clinical recommendation. Payers treat a missing or unverifiable TOUCH enrollment as grounds for denial or clawback. Before submitting any claim for HCPCS code J2323, confirm these documentation elements are in the patient’s record and accessible for audit:

• Prescriber enrollment: The ordering physician must be enrolled in TOUCH and re-authorized regularly
• Pharmacy enrollment: The dispensing pharmacy must be TOUCH-certified
• Infusion site enrollment: The administering facility must be TOUCH-certified
• Patient enrollment: The patient must be enrolled and have completed TOUCH consent
• TOUCH authorization form: A completed TOUCH Prescriber Determination form must be on file before each infusion
• JC virus antibody status: Documented in the chart; affects risk stratification and ongoing monitoring

Good practices for managing medical forms at your practice are directly relevant here. TOUCH documentation requirements generate a paper trail that must be maintained for every infusion cycle.

Digital forms that capture consent, risk assessment, and REMS authorization in the patient’s electronic record make audit defense significantly easier. For broader compliance documentation requirements, review your HIPAA-compliant medical record documentation processes to ensure TOUCH records are stored and accessed correctly.

J2323 vs Q5134: Billing the natalizumab biosimilar (Tyruko)

Q5134 is the HCPCS code for natalizumab-sztn (Tyruko), the biosimilar to Tysabri approved by the FDA. Tyruko is also billed per 1 mg, so the unit calculation is identical: 300 units for a standard 300 mg dose.

The two codes are not interchangeable on claims. If the patient receives Tysabri, bill J2323. If the patient receives Tyruko, bill Q5134. Billing the originator code for a biosimilar, or vice versa, is a coding error and may constitute fraud if it occurs systematically.

Tyruko carries its own FDA-required REMS, the TYRUKO REMS Program, which is separate from Biogen’s TOUCH program for Tysabri. Enrollment in TOUCH does not cover Tyruko administration — practices billing Q5134 must confirm separate TYRUKO REMS enrollment for the prescriber, pharmacy, and infusion site before infusing.

CMS’s JW/JZ modifier policy list also currently names J2323 but not Q5134, so verify the latest CMS list before applying either modifier to a biosimilar claim.

Payer coverage for Q5134 is evolving. Some payers have step-therapy requirements that mandate a trial of the biosimilar before approving the originator. Others cover both interchangeably when the prescriber specifies “brand necessary” with clinical justification.

Check each payer’s current specialty drug policy for the applicable biosimilar substitution and coverage rules before administering either product. You can verify the current code set using the AAPC HCPCS code lookup.

Concurrent infusion administration codes used with J2323

HCPCS code J2323 covers the drug cost only. The infusion administration service is billed separately using CPT codes from the 96365-96368 range. Correct billing requires both the drug code and the appropriate administration code.

Scope-of-practice rules vary by state, so confirm who can administer IV infusions at your practice before billing the administration code under a specific provider’s credential.

• CPT 96365: Intravenous infusion, therapeutic/diagnostic; initial, up to 1 hour (first drug billed)
• CPT 96366: Each additional hour of infusion beyond the first hour
• CPT 96367: Additional sequential infusion, up to 1 hour (if a second drug is infused after natalizumab)
• CPT 96368: Concurrent infusion (different drug infused simultaneously)

The standard natalizumab infusion runs approximately 1 hour, so most claims pair J2323 with CPT 96365. If premedication (antihistamine or corticosteroid) is administered via IV push before the natalizumab infusion, that drug is billed with its own HCPCS drug code plus CPT 96374 (IV push).

Document start and stop times for all infusions in the clinical record. Payers routinely request time documentation during audits of specialty infusion claims. Use IV therapy intake and consent documentation workflows that capture infusion start/stop times automatically at every visit.

Prior authorization and common J2323 denial reasons

Prior authorization is required by virtually all commercial payers for natalizumab, and by many Medicare Advantage plans. The authorization process typically requires clinical criteria including confirmed diagnosis, neurologist or gastroenterologist attestation, treatment history, and for Crohn’s, evidence of conventional therapy failure. Authorization periods are usually 12 months and must be renewed before expiry.

The most common denial reasons for HCPCS code J2323 claims:

• Missing JW or JZ modifier: Automatic denial under CMS policy; fix by adding the correct modifier and re-billing
• Wrong units billed: 1 unit instead of 300 units; review and correct before resubmission
• Authorization expired or missing: Verify authorization number and effective dates before each infusion
• REMS enrollment not verified: Some payers now cross-reference TOUCH enrollment; include REMS documentation in clinical record
• ICD-10 code mismatch: Diagnosis on claim does not match payer’s covered indication list; verify G35 or K50 range is used
• Setting-specific billing issues: Drug billed under Part B in a setting that routes natalizumab through Part D; verify benefit configuration before each cycle

When appealing a denied J2323 claim, include the authorization number, TOUCH REMS enrollment confirmation, the physician’s clinical notes documenting the indication and dose administered, and the JW/JZ modifier documentation. IV therapy EMR software that stores all of these documents against the patient’s treatment record makes appeal preparation significantly faster than chasing paper records across multiple systems.

Conclusion

Billing errors on J2323 are expensive. A single miscoded claim, whether it is 1 unit instead of 300 or a missing JZ modifier, can trigger a payer audit that cascades across your entire natalizumab billing history.

The code rules are specific but consistent: bill 300 units per standard dose, apply JZ when the full vial is used, apply JW on a separate line for any discarded drug, and verify TOUCH REMS enrollment before every infusion.

Pabau’s claims management software helps infusion clinics build these rules into their billing workflow, so modifier requirements, prior authorization tracking, and REMS documentation are handled at the point of care, not discovered after a denial. Book a demo to see how Pabau handles specialty drug billing for infusion practices.

Continue your research

Running an IV infusion clinic and need billing guidance? Opening an IV therapy clinic covers licensing, equipment, and operational setup for new infusion practices.

Looking to reduce infusion claim denials? Features that save private practices time explores how automation reduces billing bottlenecks in specialty practices.

Need to tighten your digital documentation process? Digital forms explains how Pabau captures intake, consent, and clinical data in one structured, HIPAA-aligned record.

Frequently asked questions